Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,510.00
Bid: 12,524.00
Ask: 12,526.00
Change: 118.00 (0.95%)
Spread: 2.00 (0.016%)
Open: 12,468.00
High: 12,556.00
Low: 12,434.00
Prev. Close: 12,392.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: Kingfisher rises as lockdown DIY boom continues

Mon, 22nd Mar 2021 08:54

(Alliance News) - Stock prices in London opened lower on Monday as shares in travel companies took a hit on the slow vaccination rollout in Europe, while DIY retailer Kingfisher bucked the trend after reporting strong annual results.

Investors grew more concerned about Europe, where the vaccination programme has stuttered and a hike in new cases has forced countries including France and Germany to reimpose lockdowns.

UK Prime Minister Boris Johnson Boris Johnson is expected to ask European leaders this week to dismiss any proposals to block coronavirus vaccine exports to the UK.

European Commission President Ursula von der Leyen has ramped up the rhetoric this weekend, saying the EU has the power to "forbid" exports, adding: "That is the message to AstraZeneca."

The warning reflects growing frustration on the continent that the EU is not getting the supplies it expected from the Anglo-Swedish drug manufacturer.

The UK PM is expected to contact his EU counterparts ahead of virtual summit on Thursday where European leaders are due to consider the matter, The Financial Times reported.

AstraZeneca was up 1.2% after it said early Monday the US phase III trial of its AZD1222 vaccine - co-invented with the University of Oxford - demonstrated statistically significant vaccine efficacy of 79% at preventing symptomatic Covid-19 and 100% efficacy at preventing severe disease and hospitalisation.

AstraZeneca said interim safety and efficacy analysis was based on 32,449 participants accruing 141 symptomatic cases of Covid-19. The trial had a 2:1 randomisation of vaccine to placebo. Vaccine efficacy was consistent across ethnicity and age. Notably, in participants aged 65 years and over, vaccine efficacy was 80%, it added.

AstraZeneca said it will continue to analyse the data and prepare for the primary analysis to be submitted to the US Food & Drug Administration for Emergency Use Authorization in the coming weeks.

The FTSE 100 index was down 50.66 points, or 0.8%, at 6,658.05. The mid-cap FTSE 250 index was down 102.19 points, or 0.5%, at 21,318.12. The AIM All-Share index was 0.2% higher at 1,199.72.

The Cboe UK 100 index was down 1.0% at 663.32. The Cboe 250 was down 0.9% at 18,978.66, and the Cboe Small Companies down 0.1% at 13,877.44.

In mainland Europe, the CAC 40 in Paris was 0.8% lower, while the DAX 30 in Frankfurt was down 0.5%.

In the FTSE 100, Kingfisher was the best blue-chip performer, up 2.5%. The DIY retailer hailed a strong annual performance as the pursuit of home improvement projects continued throughout the year.

For the financial year that ended January 31, revenue was up 7.2% at GBP12.34 billion from GBP11.51 billion a year before, while pretax profit multiplied to GBP756 million from GBP103 million.

Kingfisher declared a total dividend of 8.25 pence, having skipped payouts in financial 2020 due to the Covid-19 pandemic.

Looking ahead, Kingfisher said the new financial year has started positively, with first quarter like-for-like sales to March 18 up 24%, reflecting strong demand in the UK and France.

Adam Vettese, analyst at eToro, said: "Europe's rekindled love for DIY shows no sign of abating, with Kingfisher posting yet another strong set of results. It's rare these days to see a company in such a strong position financially and it's clear the B&Q owner has benefited greatly from people being forced to stay home."

Rightmove was up 1.6% after UBS raised the property portal to Buy from Neutral.

At the other end of the large-cap index, International Consolidated Airlines was the worst performer, down 7.1%, after Deutsche Bank downgraded the British Airways parent to Hold from Buy.

Travel stocks were lower across the board as the spat between the UK and Europe continued and amid fears the crucial summer holiday season has been put under threat by the slow vaccine rollout on the continent.

In the FTSE 250, budget airline easyJet was the worst performer, down 8.5%, Anglo-German tour operator Tui was off 6.2%, while Hungarian airline Wizz Air was 4.7% lower. In addition, Irish carrier Ryanair was 7.0% lower.

In Asia, the Japanese Nikkei 225 index finished down 2.1% on Monday. In China, the Shanghai Composite ended up 1.1%, while the Hang Seng index in Hong Kong closed 0.2% lower.

The pound was quoted at USD1.3850 early Monday, down from USD1.3874 at the London equities market close on Friday.

The euro was priced at USD1.1885, lower from USD1.1901. Against the yen, the dollar was trading at JPY108.70, down from JPY108.86.

Brent oil was quoted at USD63.82 a barrel Monday morning, down from USD64.07 at the London equities close on Friday. Gold was trading at USD1,730.57 an ounce, down from USD1,739.97.

Monday's economic calendar has eurozone current account data at 0900 GMT.

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
11 Apr 2024 17:13

FTSE 100 edges lower as financials drag

Lok'nStore surges to all-time high after buyout by Shurgard

*

Read more
11 Apr 2024 17:07

Banks weigh down Europe's STOXX 600 after ECB signals rate cuts

Outlook hike sends Ambu shares up

*

Read more
11 Apr 2024 15:56

London close: Stocks finish lower as ECB stands pat

(Sharecast News) - London's stock markets finished in negative territory on Thursday, as investors reacted to the European Central Bank's latest policy announcement and a producer price index release in the United States.

Read more
11 Apr 2024 11:50

LONDON MARKET MIDDAY: Europe takes hit on nerves ahead of ECB decision

(Alliance News) - European equities sunk lower at midday on Thursday, with sentiment hurt by hotter-than-expected inflation from the US crushing hopes of interest rate cuts.

Read more
11 Apr 2024 08:56

TOP NEWS: Astra plans 7% dividend hike for 2024 after no rise in 2023

(Alliance News) - AstraZeneca PLC said it intends to raise its annualised dividend for 2024, citing confidence in its business performance and cash generation.

Read more
11 Apr 2024 08:54

LONDON MARKET OPEN: European markets mixed ahead of ECB decision

(Alliance News) - European equities lacked direction early Thursday morning, ahead of an interest rate decision from the European Central Bank this afternoon.

Read more
11 Apr 2024 07:49

LONDON BRIEFING: Astra promises dividend hike; Darktrace ups guidance

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye the latest interest rate decision from the European Central Bank, a day after a hotter-than-expected US inflation reading.

Read more
11 Apr 2024 07:20

AstraZeneca to hike 2024 dividend by 7%

(Sharecast News) - Biopharma giant AstraZeneca has announced that it will increase its annual dividend by 7%, which the board said demonstrates its confidence in the company's performance and cash generation.

Read more
8 Apr 2024 08:36

TOP NEWS: AstraZeneca hails neurological data for Ultomiris, Soliris

(Alliance News) - AstraZeneca PLC on Monday said long-term data in generalised myasthenia gravis will underscore the "vital role" of its Ultomiris and Soliris antibodies in the treatment landscape.

Read more
8 Apr 2024 07:43

LONDON BRIEFING: Astra hails neurology data; CVS flags cyberattack

(Alliance News) - London's FTSE 100 is called to open a touch higher on Monday, ahead of an interest rate decision in the eurozone and a US inflation reading later in the week.

Read more
8 Apr 2024 07:02

AstraZeneca's Enhurtu cancer gets US green light for adult patients

(Sharecast News) - AstraZeneca and Daiichi Sankyo's Enhertu cancer drug has been approved in the US for adult patients with unresectable or metastatic solid tumours who have received prior systemic treatment and have no satisfactory alternative options.

Read more
8 Apr 2024 06:53

TOP NEWS: AstraZeneca's, Daiichi's Enhertu receives US FDA approval

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Saturday announced that the US Food & Drug Administration has approved their cancer drug conjugate for patients with metastatic HER2-positive solid tumours.

Read more
5 Apr 2024 09:42

AstraZeneca makes "breakthrough" in treating small cell lung cancer

(Alliance News) - AstraZeneca PLC on Friday reported positive results relating to its Imfinzi cancer treatment in phase III trials.

Read more
5 Apr 2024 07:50

LONDON BRIEFING: Shell to book USD600 million first-quarter write-off

(Alliance News) - London's FTSE 100 is called to open lower on Friday, with hawkish remarks from Federal Reserve policymakers and fears of ratcheting Middle East tensions giving investors little to cheer about ahead of the latest US jobs data.

Read more
5 Apr 2024 07:23

AstraZeneca announces positive lung cancer treatment trial results

(Sharecast News) - AstraZeneca announced positive high-level results from a phase three trial demonstrating significant advancements in the treatment of limited-stage small cell lung cancer (LS-SCLC) on Friday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.